This research study is being done in participants with advanced B-cell malignancies such as some types of lymphomas or leukemias. B-cell malignancies express a protein called the Bruton's tyrosine kinase (BTK), which has been shown to help the tumor cells grow and survive. The investigational drug, AC676, has been designed to recognize the BTK protein, and marks it for destruction. By destroying the BTK protein, the malignancy may be stopped from growing. "Investigational" means the study drug being tested is not approved by the FDA. This is an open-label study, meaning all patients who are eligible to participate will receive study drug. The key purposes of this study are to: ● Test the study drug at different dose levels (dose-escalation) and to determine the highest dose that can be taken without side effects that can't be tolerated (referred to as maximum tolerated dose or MTD). ● Determine what dose of

Are you a male that has been diagnosed with hormone receptor positive and HER2 negative breast cancer? If so, you may be eligible to a clinical trial comparing different endocrine therapies to treat breast cancer prior to surgery.

Have you been diagnosed with metastatic breast cancer? If so, you may be able to take part in a research study looking at the efficacy of giving a drug called enzalutamide, alone or combined with mifepristone vs standard chemotherapy.

Have you been diagnosed with Smoldering Multiple Myeloma (SMM)? Are you 40 years old or older? If so, you may be able to participate in a study to see if AL-related genes can increase the chances of SMM patients developing AL Amyloidosis in the future.

Have you been diagnosed with metastatic breast cancer? If so, you may be able to take part in a research study looking at the safety and efficacy of giving a new drug called DB-1303 vs standard chemotherapy to patients with metastatic breast cancer.

Are you dealing with multiple myeloma that keeps coming back or hasn't improved? If you are, you may be able to join a study to see if a new drug called ABBV-383 could be safe and helpful for people in your situation. You will be reimbursed for travel expenses. You will not have to pay for the drug while you take part in this study.

Have you been diagnosed with Chronic Lymphocytic Leukemia (CLL) that has transformed to aggressive lymphoma called Richter's Transformation (RT)? Then you may be able to participate in this study whose purpose is to evaluate the efficacy and safety of glofitamab as monotherapy and in combination with polatuzumab vedotin or atezolizumab for participants with Richter's Transformation (RT) that has transformed from chronic lymphocytic leukemia (CLL). These are targeted immune-based therapies standardly used to treat lymphoma and/or other cancers that may also work well for RT

Have you been diagnosed with breast cancer and completed your surgery? Has your doctor recommended hormonal therapy to help prevent your cancer from returning? You may be able to participate in a research study of a new drug called Camizestrant. Please reach out to the research team if you are interested and we will provide information regarding the next steps.

Do you have ovarian, peritoneal, or fallopian tube cancer that came back after receiving standard therapy? If so, you might be able to take part in a study that looks at a new treatment, iC9.CAR.B7-H3 cells, to test the safety of these cells and observe any side effects.

This study is for patients diagnosed with breast cancer that has spread to other parts of the body, which is called Metastatic Breast Cancer. This study will look at information from your tumor that may help choose treatments. Researchers will use this information to find out how different patients may respond to different treatments, leading to better treatments for future patients. You may not benefit personally, but your doctor may be given information which may help guide your treatments.